Short-term and long-term effects of osteoporosis therapies

Nature Reviews Endocrinology

Volumn 11, Issue 7, 2015, Pages 418-428

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CATHEPSIN K INHIBITOR; CONJUGATED ESTROGEN; DENOSUMAB; ESTROGEN; GESTAGEN; ODANACATIB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; ROMOSOZUMAB; SCLEROSTIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; CATHEPSIN K; GENETIC MARKER; MONOCLONAL ANTIBODY; SOST PROTEIN, HUMAN; STRONTIUM;

BODY MASS; BODY WEIGHT; BONE TURNOVER; COMBINATION CHEMOTHERAPY; DIET; DRUG EFFICACY; DRUG SAFETY; FEMUR SHAFT; FRACTURE; HEART INFARCTION; HUMAN; LONG TERM CARE; MORPHEA; NEPHROLITHIASIS; OSTEOMALACIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STRESS FRACTURE; THROMBOEMBOLISM; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; GENETIC MARKER; METABOLISM; OSTEOPOROTIC FRACTURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BIPHENYL COMPOUNDS; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; CALCIUM; CATHEPSIN K; DENOSUMAB; DIPHOSPHONATES; ESTROGENS; GENETIC MARKERS; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PARATHYROID HORMONE; STRONTIUM; TREATMENT OUTCOME; VITAMIN D;

EID: 84931564509     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.71     Document Type: Review

References (113)

1. Woodward, A. & Blakely, T. The Healthy Country?. A History of Life and Death in New Zealand (Auckland University Press, 2014
2. New Zealand Government. Statistics New Zealand [online], http: //www.stats.govt.nz/browse-for-stats/health/life-expectancy.aspx (2015
3. Johnell, O. & Kanis, J. A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17, 1726-1733 (2006
4. Kanis, J. A. et al. The components of excess mortality after hip fracture. Bone 32, 468-473 (2003
5. Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C. & Khaltaev, N. The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137-1141 (1994
6. Dawson-Hughes, B. et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos. Int. 19, 449-458 (2008
7. Henry, M. J., Pasco, J. A., Nicholson, G. C., Seeman, E. & Kotowicz, M. A. Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J. Clin. Densitom. 3, 261-268 (2000
8. Jones, G. et al. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos. Int. 4, 277-282 (1994
9. Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX' and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385-397 (2008
10. Nguyen, N. D., Frost, S. A., Center, J. R., Eisman, J. A. & Nguyen, T. V. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos. Int. 19, 1431-1444 (2008
11. McClung, M. R. et al. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344, 333-340 (2001
12. Jackson, R. D. et al. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354, 669-683 (2006
13. Lewis, J. R., Zhu, K. & Prince, R. L. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J. Bone Miner. Res. 27, 719-722 (2012
14. Bolland, M. J., Grey, A., Avenell, A., Gamble, G. D. & Reid, I. R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-Analysis. BMJ 342, d2040 (2011
15. Reid, I. R. Efficacy, effectiveness and side effects of medications used to prevent fractures. J. Intern. Med. http: //dx.doi.org/10.1111/joim.12339.
16. Lewis, J. R. et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-Analysis of randomized controlled trials. J. Bone Miner. Res. 30, 165-175 (2015
17. Mao, P. J. et al. Effect of calcium or vitamin D supplementation on vascular outcomes: a meta-Analysis of randomized controlled trials. Int. J. Cardiol. 169, 106-111 (2013
18. Larsen, E. R., Mosekilde, L. & Foldspang, A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3 year intervention study. J. Bone Miner. Res. 19, 370-378 (2004
19. Bolland, M. J., Grey, A., Avenell, A. & Reid, I. R. Calcium supplements increase risk of myocardial infarction. J. Bone Miner. Res. 30, 389-390 (2015
20. Reid, I. R., Bolland, M. J. & Grey, A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-Analysis. Lancet 383, 146-155 (2014
21. Avenell, A., Gillespie, W. J., Gillespie, L. D. & O'Connell, D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD000227. http: //dx.doi.org/10.1002/14651858.CD000227.pub3.
22. Chapuy, M. C. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327, 1637-1642 (1992
23. Reid, I. R. & Bolland, M. J. Calcium risk-benefit updated-new WHI analyses. Maturitas 77, 1-3 (2014
24. Robbins, J. A. et al. Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. Menopause 21, 116-123 (2014
25. Abrahamsen, B. et al. Patient level pooled analysis of 68, 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340, b5463 (2010
26. Reid, I. R. & Bolland, M. J. Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. Osteoporos. Int. 25, 2347-2357 (2014
27. Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733-759 (2008
28. Black, D. M. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 296, 2927-2938 (2006
29. Schwartz, A. V. et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J. Bone Miner. Res. 25, 976-982 (2010
30. Black, D. M. et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 30, 934-944 (2015
31. Cosman, F. et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?. J. Clin. Endocrinol. Metab. 99, 4546-4554 (2014
32. Grey, A. et al. Five years of anti-resorptive activity after a single dose of zoledronate-results from a randomized double-blind placebo-controlled trial. Bone 50, 1389-1393 (2012
33. Reid, I. R. et al. Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J. Clin. Endocrinol. Metab. 98, 557-563 (2013
34. Langdahl, B. et al. Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use [abstract]. J. Bone Miner. Res. 27 (Suppl. 1), S120 (2012
35. Watts, N. B. et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos. Int. 19, 365-372 (2008
36. Eastell, R., Hannon, R. A., Wenderoth, D., Rodriguez-Moreno, J. & Sawicki, A. Effect of stopping risedronate after long-term treatment on bone turnover. J. Clin. Endocrinol. Metab. 96, 3367-3373 (2011
37. Bauer, D. C. et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern. Med. 174, 1126-1134 (2014
38. Biswas, P. N., Wilton, L. V. & Shakir, S. A. Pharmacovigilance study of alendronate in England. Osteoporos. Int. 14, 507-514 (2003
39. Reid, I. R., Gamble, G. D., Mesenbrink, P., Lakatos, P. & Black, D. M. Characterization of and risk factors for the acute-phase response after zoledronic acid. J. Clin. Endocrinol. Metab. 95, 4380-4387 (2010
40. Reid, I. R. & Cornish, J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat. Rev. Rheumatol. 8, 90-96 (2012
41. Cartsos, V. M., Zhu, S. & Zavras, A. I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J. Am. Dent. Assoc. 139, 23-30 (2008
42. Pazianas, M., Blumentals, W. A. & Miller, P. D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos. Int. 19, 773-779 (2008
43. Lin, T. C., Yang, C. Y., Kao Yang, Y. H. & Lin, S. J. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos. Int. 25, 1503-1511 (2014
44. Assael, L. A. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J. Oral Maxillofac. Surg. 67, 35-43 (2009
45. Manfredi, M., Merigo, E., Guidotti, R., Meleti, M. & Vescovi, P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int. J. Oral Maxillofac. Surg. 40, 277-284 (2011
46. Shane, E. et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 29, 1-23 (2014
47. Schilcher, J., Koeppen, V., Aspenberg, P. & Michaëlsson, K. Risk of atypical femoral fracture during and after bisphosphonate use. N. Engl. J. Med. 371, 974-976 (2014
48. Schilcher, J., Koeppen, V., Aspenberg, P. & Michaëlsson, K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 86, 100-107 (2015
49. Dell, R. M. et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J. Bone Miner. Res. 27, 2544-2550 (2012
50. Schilcher, J., Michaelsson, K. & Aspenberg, P. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 364, 1728-1737 (2011
51. Black, D. M. et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 362, 1761-1771 (2010
52. Meier, R. P., Perneger, T. V., Stern, R., Rizzoli, R. & Peter, R. E. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch. Intern. Med. 172, 930-936 (2012
53. Lindsay, R., Hart, D. M., Forrest, C. & Baird, C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 2, 1151-1153 (1980
54. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002
55. Anderson, G. L. et al. Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 291, 1701-1712 (2004
56. Rossouw, J. E. et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465-1477 (2007
57. Grese, T. A. et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl Acad. Sci. USA 94, 14105-14110 (1997
58. Delmas, P. D. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647 (1997
59. Reid, I. R. et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch. Intern. Med. 164, 871-879 (2004
60. Ettinger, B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637-645 (1999
61. Sharifi, M. & Lewiecki, E. M. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev. Clin. Pharmacol. 7, 281-291 (2014
62. Mirkin, S., Ryan, K. A., Chandran, A. B. & Komm, B. S. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas 77, 24-31 (2014
63. Lindsay, R., Gallagher, J. C., Kagan, R., Pickar, J. H. & Constantine, G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil. Steril. 92, 1045-1052 (2009
64. Rosen, C. J. (Ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 8th edn (American Society for Bone and Mineral Research, 2013
65. Reid, I. R. et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Miner. Res. 25, 2256-2265 (2010
66. Miller, P. D. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43, 222-229 (2008
67. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009
68. Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809-1822 (2007
69. Papapoulos, S. et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension [abstract]. J. Bone Miner. Res. 28 (Suppl. 1), S503 (2013
70. Ferrari, S. et al. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the FREEDOM extension [abstract]. J. Bone Miner. Res. 28 (Suppl. 1), S6 (2013
71. Black, D. M. et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 27, 243-254 (2012
72. Bone, H. G. et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189-1199 (2004
73. Peddi, P., Lopez-Olivo, M. A., Pratt, G. F. & Suarez-Almazor, M. E. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-Analysis. Cancer Treat. Rev. 39, 97-104 (2013
74. Geller, M. et al. Early findings from Prolia' post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. Osteoporos Int. 25 (Suppl. 2), 56-57 (2014
75. Reid, I. R., Pybus, J., Lim, T. M., Hannon, S. & Ibbertson, H. K. The assessment of intestinal calcium absorption using stable strontium. Calcif. Tissue Int. 38, 303-305 (1986
76. Meunier, P. J. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350, 459-468 (2004
77. Reginster, J. Y. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90, 2816-2822 (2005
78. Recker, R. R. et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J. Bone Miner. Res. 24, 1358-1368 (2009
79. Iolascon, G. et al. Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin. Exp. Res. 25, S137-S141 (2013
80. Le Merlouette, M. et al. Strontium ranelate-induced DRESS syndrome. Ann. Dermatol. Venereol. 138, 124-128 (2011
81. Tan, K. W., Wang, Y. S. & Tay, Y. K. Stevens-Johnson syndrome due to strontium ranelate. Ann. Acad. Med. Singapore 40, 510-511 (2011
82. Medicines and Healthcare Products Regulatory Agency. Strontium ranelate (Protelos): risk of serious cardiac disorders-restricted indications, new contraindications, and warnings. Drug Safety Update 6, S1 (2013
83. Bolland, M. J. & Grey, A. A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open 4, e005787 (2014
84. Bolland, M. J. et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-Analysis. BMJ 341, C3691 (2010
85. Slovik, D. M. et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1, 25 dihydroxyvitamin D. J. Bone Miner. Res. 1, 377-381 (1986
86. Bilezikian, J. P. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J. Clin. Endocrinol. Metab. 94, 335-339 (2009
87. Arlot, M. et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 20, 1244-1253 (2005
88. McClung, M. R. et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165, 1762-1768 (2005
89. Lindsay, R. et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350, 550-555 (1997
90. Boonen, S. et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93, 852-860 (2008
91. Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001
92. Lindsay, R. et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164, 2024-2030 (2004
93. Greenspan, S. L. et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326-339 (2007
94. Nakamura, T. et al. Randomized teriparatide human parathyroid hormone (PTH) 1-34 once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J. Clin. Endocrinol. Metab. 97, 3097-3106 (2012
95. Hattersley, G. et al. Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis. Bone Abstracts [online], http: //www.bone-Abstracts.org/ba/0001/ba0001oc5.5.htm (2013
96. The Endocrine Society. Investigational osteoporosis drug, abaloparatide, lowers fracture risk. EurekAlert.org [online], http: //www.eurekalert.org/pub-releases/2015-03/tes-iod030515.php (2015
97. Black, D. M. et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215 (2003
98. Cosman, F. et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503-511 (2011
99. Leder, B. Z. et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J. Clin. Endocrinol. Metab. 99, 1694-1700 (2014
100. Cosman, F. et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94, 3772-3780 (2009
101. Vahle, J. L. et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol. 32, 426-438 (2004
102. Bang, U. C., Hyldstrup, L. & Jensen, J. E. The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos. Int. 25, 639-644 (2014
103. Andrews, E. B. et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J. Bone Miner. Res. 27, 2429-2437 (2012
104. Gauthier, J. Y. et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 18, 923-928 (2008
105. Bone, H. G. et al. Odanacatib, a cathepsin K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937-947 (2010
106. Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242-251 (2011
107. McClung, M. Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis. Results from the phase III long-term odanacatib fracture trial (LOFT). Presented at the 2014 Annual Meeting of the American Society for Bone and Mineral Research, Houston, TX.
108. Merck. Update on phase III trial for odanacatib, Merck's investigational cat K inhibitor for osteoporosis. Mercknewsroom.com [online], http: //www.mercknewsroom.com/press-release/research-development-news/update-phase-iii-trial-odanacatib-mercks-investigational-cat (2012
109. Ominsky, M. S. et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 26, 1012-1021 (2011
110. Padhi, D., Jang, G., Stouch, B., Fang, L. A. & Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19-26 (2011
111. McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412-420 (2014
112. US National Library of Medicine. ClinicalTrials.gov [online], https: //clinicaltrials.gov/ct2/show/NCT01575834?term=NCT01575834&rank=1 (2014
113. Murad, M. H. et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-Analysis. J. Clin. Endocrinol. Metab. 97, 1871-1880 (2012